LYNX THERAPEUTICS INC
10-Q, EX-27.1, 2000-11-14
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Previous: LYNX THERAPEUTICS INC, 10-Q, 2000-11-14
Next: CLARUS CORP, 10-Q, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           4,769
<SECURITIES>                                    15,049
<RECEIVABLES>                                    4,131
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                25,654
<PP&E>                                          23,358
<DEPRECIATION>                                   8,083
<TOTAL-ASSETS>                                  41,626
<CURRENT-LIABILITIES>                            9,158
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        75,671
<OTHER-SE>                                    (63,214)
<TOTAL-LIABILITY-AND-EQUITY>                    41,626
<SALES>                                              0
<TOTAL-REVENUES>                                 9,275
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                21,791
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 108
<INCOME-PRETAX>                                (8,494)
<INCOME-TAX>                                       119
<INCOME-CONTINUING>                            (8,613)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (8,613)
<EPS-BASIC>                                     (0.76)
<EPS-DILUTED>                                   (0.76)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission